The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study | MicrobiomeTrials← Back to trialsNCT06796504
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-04-17Est. Completion: 2027-12-31
Enrollment target: 60 participants Locations- University of California Irvine Center for Clinical Research, Irvine, California, United States
- Shepherd Center, Atlanta, Georgia, United States
- Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- Minnesota Center for Multiple Sclerosis, Plymouth, Minnesota, United States
- The University of Texas Health Science Center at Houston, Houston, Texas, United States
- UW Medicine Multiple Sclerosis Center-Northwest, Seattle, Washington, United States
- West Virginia University, Morgantown, West Virginia, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Multiple Sclerosis (MS) - Relapsing-remitting
The purpose of the research study is to explore new retinal imaging biomarkers of immune cell activity in MS during use …
Baltimore, United StatesEst. completion Dec 30, 2027
Multiple Sclerosis
This single-blind, randomized controlled clinical trial aims to evaluate the long-term effects of using sensorimotor ins…
Salamanca, SpainEst. completion Dec 2026